Clinical Trial

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

Study acronym: DISCERN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-17; most recent amendment 2024-11-20.
Status change: Recruiting → Active, Not Recruiting 2024-08-14
Status change: Not Yet Recruiting → Recruiting 2023-10-25
Trial Details
NCT Number NCT05878288
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: University of Melbourne, University of Adelaide, Monash University, Regeneron Pharmaceuticals, Sanofi
Conditions Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin Cancer
Enrollment 11 participants
Start Date 2023-05-26
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2024-11-21